All In Biotech

Drug Trial Radar · NCT07939971

A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML

A Phase 1b Dose-Escalation and Dose-Optimization Study of TBS-2025 Monotherapy in Participants With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Lead sponsor
TuHURA Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to learn if TBS-2025 is safe to administer to participants with relapsed/refractory (r/r) Acute Myeloid Leukemia (AML). The main questions it aims to answer are: * What medical problems do adult participants have when taking TBS-2025? * What does the body do from the time TBS-2025 enters the body until it is completely gone? * What is the best dose of TBS-2025 to give to participants? * Does TBS-2025 work to treat r/r AML? Participants will: * Take TBS-2025 every 2 weeks * Visit the clinic every 1 to 2 weeks for checkups and tests

Conditions

  • Acute Myeloid Leukemia

Interventions

  • TBS-2025Biological

    TBS-2025 is a fully human IgG1-kappa monoclonal antibody that binds specifically to the hVISTA-ECD and blocks interaction with endogenous VISTA ligands.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: At the end of Cycle 1 ( each cycle is 28 days)
  2. Number of participants with an AETime frame: Baseline through study completion, an average of 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.